We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor.
- Authors
Kim, Kevin B; Kefford, Richard; Pavlick, Anna C; Infante, Jeffrey R; Ribas, Antoni; Sosman, Jeffrey A; Fecher, Leslie A; Millward, Michael; McArthur, Grant A; Hwu, Patrick; Gonzalez, Rene; Ott, Patrick A; Long, Georgina V; Gardner, Olivia S; Ouellet, Daniele; Xu, Yanmei; DeMarini, Douglas J; Le, Ngocdiep T; Patel, Kiran; Lewis, Karl D
- Abstract
BRAF mutations promote melanoma cell proliferation and survival primarily through activation of MEK. The purpose of this study was to determine the response rate (RR) for the selective, allosteric MEK1/MEK2 inhibitor trametinib (GSK1120212), in patients with metastatic BRAF-mutant melanoma.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Vol 31, Issue 4, p482
- ISSN
1527-7755
- Publication type
Journal Article
- DOI
10.1200/JCO.2012.43.5966